Target specificity of Nanobodies TM directed against amyloid peptides

AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeOther
SubjectAlzheimer's disease; amyloid peptides; Nanobodies
AbstractThe lack of early objective diagnosis and disease modifying therapy remains the major medical problem in Alzheimer's disease (AD). The promise of different active and passive immunization strategies that are targeting the amyloid peptides must be explored as wide as possible. Here we report for the first time a biochemical and immuno-histochemical characterization and validation of "Nanobodies TM" directed against amyloid peptides. Nanobodies are therapeutic proteins derived from so-called heavy chain antibodies in the Camelidae that are experimentally derived from llamas.
LanguageEnglish
AffiliationNRC Institute for Biological Sciences; National Research Council Canada
Peer reviewedYes
NPARC number21275184
Export citationExport as RIS
Report a correctionReport a correction
Record identifier613270c1-1ae3-4fe7-8b4e-113fa3a7a9cb
Record created2015-05-22
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)